Vanda Pharmaceuticals Inc.
VNDA
$4.92
-$0.10-1.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -84.20M | -66.94M | -44.25M | -18.90M | -16.39M |
| Total Depreciation and Amortization | 8.03M | 7.94M | 7.89M | 8.13M | 7.32M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.67M | -10.29M | -4.67M | 1.57M | -4.15M |
| Change in Net Operating Assets | 6.00M | 4.49M | -15.45M | -6.56M | -4.46M |
| Cash from Operations | -81.84M | -64.80M | -56.47M | -15.76M | -17.67M |
| Capital Expenditure | -1.11M | -1.11M | -2.44M | -4.72M | -105.42M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 55.10M | 45.79M | 47.13M | -12.71M | 40.22M |
| Cash from Investing | 53.99M | 44.68M | 44.69M | -17.43M | -65.21M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.51M | -989.00K | -564.00K | -155.00K | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -915.00K | -915.00K | -915.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.42M | -1.90M | -1.48M | -155.00K | -- |
| Foreign Exchange rate Adjustments | -199.00K | 49.00K | -100.00K | -163.00K | 189.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.48M | -21.97M | -13.36M | -33.51M | -82.69M |